Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (15)

2021

  1. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

    Neurology, Vol. 97, Núm. 14, pp. E1367-E1381

2020

  1. A Spanish consensus on the use of safinamide for parkinson’s disease in clinical practice

    Brain Sciences, Vol. 10, Núm. 3

  2. Erratum: A Spanish consensus on the use of safinamide for parkinson’s disease in clinical practice. (Brain sci. (2020) 10, 176)

    Brain Sciences

2018

  1. «Apuntes en Neurologia»: una sintesis de la evidencia en trastornos neurologicos comunes paroxisticos y en trastornos neurodegenerativos

    Revista de neurologia, Vol. 67, Núm. s01, pp. S1-S21

2016

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression

    BMC Neurology, Vol. 16, Núm. 1

  2. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2R1441G Parkinson's disease

    Movement Disorders, Vol. 31, Núm. 3, pp. 335-343

  3. Erratum to: COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression [BMC Neurol. 16, (2015), 26] DOI: 10.1186/s12883-016-0548-9

    BMC Neurology

2012

  1. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation

    Movement Disorders, Vol. 27, Núm. 1, pp. 146-150

2009

  1. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats

    Psychopharmacology, Vol. 204, Núm. 2, pp. 241-250

2008

  1. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study

    Movement Disorders, Vol. 23, Núm. 8, pp. 1130-1136

  2. The basal ganglia in Parkinson's disease: Current concepts and unexplained observations

    Annals of Neurology, Vol. 64, Núm. SUPPL. 2

2007

  1. Levodopa-induced dyskinesias in Parkinson's disease

    Handbook of Clinical Neurology (Elsevier), pp. 185-218

2005

  1. Optimization of use of levodopa in Parkinson's disease: Role of levodopa-carbidopa-entacapone combination

    Neurologia, Vol. 20, Núm. 4, pp. 180-188

  2. Transcultural comparison of psychogenic movement disorders

    Movement Disorders, Vol. 20, Núm. 10, pp. 1343-1345

2004

  1. The origin of motor fluctuations in Parkinson's disease: Importance of dopaminergic innervation and basal ganglia circuits

    Neurology, Vol. 62, Núm. 1 SUPPL. 1